Despite the fact that the industry inked more than 1,000 deals last year, it appears that biopharma companies are not losing their appetite for dealmaking. According to data from BioWorld and Cortellis Deals Intelligence, there were 271 deals signed in the first quarter of 2018, on par with 2017 first quarter transactions.
A study has identified common genetic variants in the Chinese population contributing to the risk of developing Alzheimer's disease (AD) that possibly exert functional effects through the immune system, which could have important implications for AD management.
The search continues for promising biomarkers and effective disease-modifying therapies for AD. The current drug development approaches mainly target the disease's hallmark pathology of amyloid-beta (Abeta) protein accumulation in the brain leading to Abeta plaque deposition.
READ MORE »- New approach breaches 'firewall' between GWAS, effectors »
- Genetic Alzheimer’s risk factor repaired in human brain cells »
- Platelets, antibodies form anaphylaxis alliance »
- Compound accelerates post-stroke motor function recovery »
- Researchers disagree on whether adults make new brain cells »
- Rabies virus vector gives immune system second chance at fighting West Nile »
- New approaches could broaden antibiotic space »
- Autophagy role in memory may yield anxiety treatments »
- New approaches could broaden antibiotic space »
- If no one reads it, what’s the purpose of a drug label?March 29, 2018 | 11:29 PM | Posted by: Mari Serebrov
- The opioid crisis: A venture in need of a GAIN?February 16, 2018 | 6:01 PM | Posted by: Jennifer Boggs
- Real-world optics of biopharma price hikesFebruary 03, 2018 | 12:11 AM | Posted by: Mari Serebrov
- Science for the season: BioWorld’s 11th annual Holiday Gift GuideDecember 01, 2017 | 12:54 AM | Posted by: Marie Powers
- Drug quality from a patient’s perspectiveSeptember 10, 2017 | 2:06 PM | Posted by: Mari Serebrov
Partners in Focus
